logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
S

Subotheni Thavaneswaran

nhmrc clinical trials centre
H指数:11
被引数:505

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Tucatinib and trastuzumab in advanced cancers with HER2 mutations or amplifications: a molecular screening and therapeutics (MoST) program substudy

Tucatinib和曲妥珠单抗在HER2突变或扩增的晚期癌症中的研究：分子筛查和治疗（MoST）计划子研究

npj Precision Oncology
IF8
2026-07-240
OA
Benjamin Y. Kong; Frank Po-Yen Lin; David Espinoza; Mason Aberoumand; Subotheni Thavaneswaran; Tarek Meniawy; Jayesh Desai; Rosemary Harrup; Sudarshan Selva Nayagam; Michail Charakidis; Katharine Cuff; Lucille Sebastian; Chee Khoon Lee; Patrick Wheeler; Maya Kansara; John P. Grady; David M. Thomas; Mandy L. Ballinger; John Simes; David Goldstein
PATH-18. Investigating the role of CDKN2A loss in IDH-mutant gliomas: biological insights beyond tumour grading

PATH-18. 研究CDKN2A缺失在IDH突变型胶质瘤中的作用：超越肿瘤分级的生物学见解

Neuro-Oncology
IF13.4
2025-11-110
OA
Alexander Yuile; Laveniya Satgunaseelan; Kimberly L Alexander; Subotheni Thavaneswaran; Hao-Wen Sim; Ashraf Zaman; Joseph Powell; Aijia Meng; Cecile Escher; Joe Q Wei; Grace Wei; Maggie Lee; Michael E Buckland; Benjamin Y Kong; Marina Kastelan; Mark Wong; Isabella Wilson; Angela Bayly; Winny Varikatt; Zarnie Lwin; Michael Rodriguez; Hwei Choo Soh; Anthony Gill; Razia Zakarya; Michael F Back; Nick Pavlakis; David L Chan; Adrian Lee; Helen R Wheeler; Amanda L Hudson
Low and Intermediate Grade Glioma Umbrella Study of Molecular Guided TherapieS (LUMOS2) study

低级别和间级别胶质瘤伞式研究：分子指导疗法（LUMOS2）研究

NEURO-ONCOLOGY
IF13.4
2025-11-010
OAAI
Thavaneswaran, Subotheni; Koh, Eng-Siew; Sim, Hao-Wen; Ballinger, Mandy L.; Thomas, David M.; Barnes, Elizabeth H.; Kong, Ben; O'callaghan, Chris; Pitz, Marshall; Hawkins, Cynthia; Roberge, David; Pallimulla, Sachie; Ralston, Laurence; Yip, Sonia; Day, Bryan W.; Verhaak, Roel G. W.; Buckland, Michael; Amanuel, Benhur; Simes, John; De Lourenco, Richard Abreu; Solano, Nuria Zamora; Calder, Ros; Adda, Lucas; Ahern, Elizabeth; Cooper, Adam; Dowling, Anthony; Harrup, Rosemary; Kichenadasse, Ganessan; Lau, Brandon; Lynam, James; Lwin, Zarnie; Wheeler, Helen; Whittle, James R.; Norrie, Andrew; Harrison, Rebecca; Mason, Warren P.; De Robles, Paula; Maddula, Meghana; Gan, Hui K.
A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation
NPJ PRECISION ONCOLOGY
IF8
2024-09-091
OAAI
Thavaneswaran, Subotheni; Lin, Frank; Grady, John P.; Espinoza, David; Huang, Min Li; Chinchen, Sarah; Sebastian, Lucille; Kansara, Maya; Mersiades, Tony; Lee, Chee Khoon; Desai, Jayesh; Grimison, Peter; Brown, Michael; Millward, Michael; Harrup, Rosemary; O'Byrne, Ken; Nagrial, Adnan; Craft, Paul; Simes, John; Joshua, Anthony M.; Thomas, David M.
Tucatinib and trastuzumab in advanced cancers with HER2 mutations or amplification: A molecular screening and therapeutics (MoST) program substudy

Tucatinib和Trastuzumab在HER2突变或扩增的晚期癌症中的应用：一项分子筛查与治疗（MoST）计划亚研究

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Kong, B. Y.; Lin, F. P-Y.; Espinoza, D.; Thavaneswaran, S.; Meniawy, T.; Desai, J.; Harrup, R.; Selva-Nayagam, S.; Charakidis, M.; Cuff, K.; Sebastian, L.; Lee, C. K.; Chinchen, S.; Thomas, D. M.; Ballinger, M. L.; Simes, J.; Goldstein, D.
Phase II trial of vemurafenib (VEM) and cobimetinib (COB) in BRAF V600-mutated solid tumours and first-line (1L) non-small cell lung cancer (NSCLC): Australian molecular screening and therapeutics (MoST) substudy 12

vemurafenib（VEM）和cobimetinib（COB）在BRAF V600突变实体瘤和一线（1L）非小细胞肺癌（NSCLC）中的II期试验：澳大利亚分子筛查和治疗（MoST）子研究12

ANNALS OF ONCOLOGY
IF65.4
2024-09-010
PRE
Lin, F. P.; Mersiades, A.; Lee, J.; Xu, W.; Chinchen, S.; Charakidis, M.; Thavaneswaran, S.; Hughes, B. G. M.; Underhill, C. R.; Takhar, H. S.; Harrup, R.; Nagrial, A.; Millward, M.; Desai, J.; Espinoza, D.; Lee, C. K.; Solomon, B. J.; Simes, J.; Pavlakis, N.; Thomas, D.
Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials
INTERNATIONAL JOURNAL OF CANCER
IF4.7
2023-07-1013
OA
Zeverijn, Laurien J.; Looze, Eleonora J.; Thavaneswaran, Subotheni; Henegouwen, J. Maxime van Berge; Simes, Robert J.; Hoes, Louisa R.; Sjoquist, Katrin M.; van der Wijngaart, Hanneke; Sebastian, Lucille; Geurts, Birgit S.; Lee, Chee K.; de Wit, Gijsbrecht F.; Espinoza, David; Roepman, Paul; Lin, Frank P.; Jansen, Anne M. L.; de Leng, Wendy W. J.; van der Noort, Vincent; Leek, Lindsay V. M.; de Vos, Filip Y. F. L.; van Herpen, Carla M. L.; Gelderblom, Hans; Verheul, Henk M. W.; Thomas, David M.; Voest, Emile E.
MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG)

MONARCC: 帕尼单抗单药治疗和帕尼单抗联合5-氟尿嘧啶作为RAS和BRAF野生型转移性结直肠癌一线治疗的随机II期研究: 澳大利亚胃肠道试验组 (AGITG) 的研究

BMC CANCER
IF3.4
2021-08-181
OAAI
Siu, Ho Wai Derrick; Tebbutt, Niall; Chantrill, Lorraine; Karapetis, Chris; Steer, Christopher; Wilson, Kate; Espinoza, David; Bailey, Lisa; Yip, Sonia; Cuff, Jeff; Pavlakis, Nick; Thavaneswaran, Subotheni; Briscoe, Karen; Srivastav, Ratnesh; Shannon, Jennifer; Segelov, Eva; Tie, Jeannie; Caird, Susan; Francesconi, Alessandra; Price, Timothy; Wuttke, Melanie; Ladwa, Rahul; Sjoquist, Katrin; Burge, Matthew

研究方向

暂未获取到该数据
D
David M. Thomas
H 指数:76论文数:609被引数:2.4万
M
Mandy L. Ballinger
H 指数:31论文数:208被引数:3,485
F
Frank Lin
H 指数:19论文数:109被引数:1,260
C
Chee Khoon Lee
H 指数:42论文数:302被引数:1.2万
M
Maya Kansara
H 指数:17论文数:67被引数:2,882
J
Jayesh Desai
H 指数:67论文数:651被引数:2.9万
J
John Simes
H 指数:15论文数:86被引数:2,114
N
Nick Pavlakis
H 指数:62论文数:576被引数:1.6万
J
John P. Grady
H 指数:26论文数:94被引数:2,279
R
Rosemary Harrup
H 指数:20论文数:157被引数:2,376